Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler,Scott T. C. Shepherd,Lewis Au,Katalin A. Wilkinson,Mary Wu,Fiona Byrne,Maddalena Cerrone,Andreas M. Schmitt,Nalinie Joharatnam-Hogan,Benjamin Shum,Zayd Tippu,Karolina Rzeniewicz,Laura Amanda Boos,Ruth Harvey,Eleanor Carlyle,Kim Edmonds,Lyra Del Rosario,Sarah Sarker,Karla Lingard,Mary Mangwende,Lucy Holt,Hamid Ahmod,Justine Korteweg,Tara Foley,Jessica Bazin,William Gordon,Taja Barber,Andrea Emslie-Henry,Wenyi Xie,Camille L. Gerard,Daqi Deng,Emma C. Wall,Ana Agua-Doce,Sina Namjou,Simon Caidan,Mike Gavrielides,James I. MacRae,Gavin Kelly,Kema Peat,Denise Kelly,Aida Murra,Kayleigh Kelly,Molly O’Flaherty,Lauren Dowdie,Natalie Ash,Firza Gronthoud,Robyn L. Shea,Gail Gardner,Darren Murray,Fiona Kinnaird,Wanyuan Cui,Javier Pascual,Simon Rodney,Justin Mencel,Olivia Curtis,Clemency Stephenson,Anna Robinson,Bhavna Oza,Sheima Farag,Isla Leslie,Aljosja Rogiers,Sunil Iyengar,Mark Ethell,Christina Messiou,David Cunningham,Ian Chau,Naureen Starling,Nicholas Turner,Liam Welsh,Nicholas van As,Robin L. Jones,Joanne Droney,Susana Banerjee,Kate C. Tatham,Mary O’Brien,Kevin Harrington,Shreerang Bhide,Alicia Okines,Alison Reid,Kate Young,Andrew J. S. Furness,Lisa Pickering,Charles Swanton,Sonia Gandhi,Steve Gamblin,David L. V. Bauer,George Kassiotis,Sacheen Kumar,Nadia Yousaf,Shaman Jhanji,Emma Nicholson,Michael Howell,Susanna Walker,Robert J. Wilkinson,James Larkin,Samra Turajlic,,
DOI: https://doi.org/10.1038/s43018-021-00274-w
IF: 22.7
2021-10-27
Nature Cancer
Abstract:Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.